Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
European Urology
|
November 25, 2019
Re: <sup>18</sup>F-Fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence After Prostatectomy: A Prospective, Single-centre, Single-arm, Comparative Imaging Trial
Samantha Koschel, Jada Kapoosr, James Buteau, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 7, 2026
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer
Pierre-Yves Cren, James Buteau, Umma Fatema, et al.
Future Oncology (London, England)
|
July 6, 2021
The application of theranostics in different stages of prostate cancer
Omar Alghazo, Renu Eapen, Samantha Koschel, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
May 6, 2024
Comparison of quantitative whole body PET parameters on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer
Narjess Ayati, Lachlan McIntosh, James Buteau, et al.
European Urology Open Science
|
April 27, 2023
A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies
Gideon Ptasznik, Daniel Moon, James Buteau, et al.
European Urology Focus
|
May 28, 2026
Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET
Abdullah Al-Khanaty, David Hennes, Michael S Hofman, et al.
BJU International
|
June 20, 2020
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option
Nikhil Mayor, Niranjan J Sathianathen, James Buteau, et al.
BJU International
|
April 1, 2022
High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer
Gideon Ptasznik, Nathan Papa, Brian D Kelly, et al.
BJU International
|
May 16, 2022
Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer
Jonathan S O'Brien, Aoife McVey, Brian D Kelly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
Michael S Hofman, Alicia Corlett, Cameron Pain, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
European Urology
|
November 25, 2019
Re: <sup>18</sup>F-Fluciclovine PET-CT and <sup>68</sup>Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence After Prostatectomy: A Prospective, Single-centre, Single-arm, Comparative Imaging Trial
Samantha Koschel, Jada Kapoosr, James Buteau, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 7, 2026
Optimizing Care for Patients With Metastatic Castration-Resistant Prostate Cancer
Pierre-Yves Cren, James Buteau, Umma Fatema, et al.
Future Oncology (London, England)
|
July 6, 2021
The application of theranostics in different stages of prostate cancer
Omar Alghazo, Renu Eapen, Samantha Koschel, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society
|
May 6, 2024
Comparison of quantitative whole body PET parameters on [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT using ordered Subset Expectation Maximization (OSEM) vs. bayesian penalized likelihood (BPL) reconstruction algorithms in men with metastatic castration-resistant prostate cancer
Narjess Ayati, Lachlan McIntosh, James Buteau, et al.
European Urology Open Science
|
April 27, 2023
A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies
Gideon Ptasznik, Daniel Moon, James Buteau, et al.
European Urology Focus
|
May 28, 2026
Avoiding Prostate Biopsy in Early Prostate Cancer Detection: From Liquid Biopsy to PSMA-PET
Abdullah Al-Khanaty, David Hennes, Michael S Hofman, et al.
BJU International
|
June 20, 2020
Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option
Nikhil Mayor, Niranjan J Sathianathen, James Buteau, et al.
BJU International
|
April 1, 2022
High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer
Gideon Ptasznik, Nathan Papa, Brian D Kelly, et al.
BJU International
|
May 16, 2022
Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer
Jonathan S O'Brien, Aoife McVey, Brian D Kelly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
Michael S Hofman, Alicia Corlett, Cameron Pain, et al.
Page
of 2